Momelotinib During and After HCT in Myelofibrosis
Key claim: A phase I study is evaluating the safety and tolerability of momelotinib administered during and after hematopoietic cell transplantation in myelofibrosis patients.
Abstract
This is a single-center, open-label, phase I study to determine the safety and tolerability of momelotinib in patients with myelofibrosis during and after hematopoietic cell transplantation (HCT).
Why this matters
Momelotinib’s distinctive ACVR1 inhibition (and resulting hepcidin suppression / anemia benefit) makes it mechanistically appealing for the peri-transplant MF setting, where cytopenias and slow erythroid engraftment are major problems — gaps that ruxolitinib does not directly address. A prospective phase I evaluation specifically during and after HCT begins to define whether momelotinib can safely occupy the bridging-plus-GVHD-prophylaxis niche currently dominated by ruxolitinib. If tolerable, it expands the JAK-inhibitor toolkit for transplant decision-making, particularly for anemic or transfusion-dependent candidates.